Genmab A/S (NASDAQ:GMAB) Sets New 12-Month High – Time to Buy?

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) hit a new 52-week high on Tuesday . The company traded as high as $33.67 and last traded at $33.65, with a volume of 1371892 shares changing hands. The stock had previously closed at $33.06.

Analyst Upgrades and Downgrades

GMAB has been the subject of a number of research analyst reports. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. HC Wainwright boosted their target price on Genmab A/S from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price for the company in a report on Tuesday, September 23rd. Truist Financial reiterated a “buy” rating and set a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Finally, Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $39.75.

Genmab A/S Price Performance

The firm has a market capitalization of $21.62 billion, a price-to-earnings ratio of 14.32, a P/E/G ratio of 1.69 and a beta of 0.90. The stock has a fifty day moving average of $30.77 and a two-hundred day moving average of $26.80.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. On average, research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Osaic Holdings Inc. increased its holdings in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares in the last quarter. CWM LLC grew its position in Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares during the last quarter. Brown Brothers Harriman & Co. increased its position in shares of Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares during the last quarter. Finally, AlphaCore Capital LLC purchased a new stake in Genmab A/S during the second quarter worth about $44,000. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.